Literature DB >> 21339223

Treatment of chronic inflammatory diseases with implantable medical devices.

Ralph J Zitnik1.   

Abstract

Implantable medical devices are finding increasing use in the treatment of diseases traditionally targeted with drugs. It is well established that the cholinergic anti-inflammatory pathway serves as a physiological regulator of inflammatory responses, but stimulation of this pathway therapeutically by electrical stimulation of the vagus nerve can also diminish excessive or dysregulated states of inflammation. Recent data from a wide variety of animal models, as well as evidence of reduced vagal tone in rheumatoid arthritis and other inflammatory diseases, support the rationale for, and feasibility of, developing implantable vagal nerve stimulation devices to treat chronic inflammation in humans.

Entities:  

Mesh:

Year:  2011        PMID: 21339223     DOI: 10.1136/ard.2010.138677

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  4 in total

Review 1.  The brain-joint axis in osteoarthritis: nerves, circadian clocks and beyond.

Authors:  Francis Berenbaum; Qing-Jun Meng
Journal:  Nat Rev Rheumatol       Date:  2016-06-16       Impact factor: 20.543

Review 2.  Cardiac autonomic nerve stimulation in the treatment of heart failure.

Authors:  Mariko Kobayashi; Alex Massiello; Jamshid H Karimov; David R Van Wagoner; Kiyotaka Fukamachi
Journal:  Ann Thorac Surg       Date:  2013-06-05       Impact factor: 4.330

3.  Optimal intervention time of vagal stimulation attenuating myocardial ischemia/reperfusion injury in rats.

Authors:  Qiang Wang; Rui-Ping Li; Fu-Shan Xue; Shi-Yu Wang; Xin-Long Cui; Yi Cheng; Gao-Pu Liu; Xu Liao
Journal:  Inflamm Res       Date:  2014-10-08       Impact factor: 4.575

4.  Pharmacological potentiation of the efferent vagus nerve attenuates blood pressure and renal injury in a murine model of systemic lupus erythematosus.

Authors:  Grace S Pham; Lei A Wang; Keisa W Mathis
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2018-10-17       Impact factor: 3.619

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.